Δημοσίευση

Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.

ΤίτλοςInhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.
Publication TypeJournal Article
Year of Publication2018
AuthorsSapalidis, K., Zarogoulidis P., Huang H., Bai C., Wen Y., Wang L., Boniou K., Karapantzos I., Karapantzou C., Karanikas M., Thomaidis V., Kosmidis C., Sardeli C., Benhassen N., Man Y-G., Florou M. C., Mantalovas S., Laskou S., Giannakidis D., Koulouris C., Amaniti A., Kesisoglou I., & Hohenforst-Schmidt W.
JournalJ Cancer
Volume9
Issue6
Pagination1121-1126
Date Published2018
ISSN1837-9664
Abstract

Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.

DOI10.7150/jca.24397
Alternate JournalJ Cancer
PubMed ID29581792
PubMed Central IDPMC5868180

Επικοινωνία

Γραμματεία Τμήματος Ιατρικής T.K. 54124 Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα social networks.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.